Themis Medicare Limited

BSE: 530199 NSE: THEMISMED
Themis Medicare Limited - pharma in Vapi, Gujarat, India. FY 2026 financials & compliance.
CIN L24110GJ1969PLC001590 Incorporated 31 May 1969 ROC Ahmedabad HQ Vapi, Gujarat, India
Active Listed - NSE: THEMISMED · BSE: 530199 Public Limited Company pharma
Data last updated
Market Cap
₹898 Cr
THEMISMED · NSE
Share Price
₹94.83
-2.76% today
Revenue
₹342 Cr
FY 2025-26 · -15.6% YoY
EBITDA
−₹0.48 Cr
Margin -0.1%
Net Profit
₹1.65 Cr
FY 2025-26 · -94.5% YoY
ROE
0.5%
ROCE 2.9%
Debt / Equity
0.25
Interest cover -99.0x
Authorised capital
₹10 Cr
Registered with MCA

About Themis Medicare Limited

Data last updated:

Themis Medicare Limited is a public limited company based in Vapi, Gujarat, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 31 May 1969 and has been in existence for over 57 years.

Its director Dinesh Shantilal Patel and family are #912 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24110GJ1969PLC001590. It is a listed company as per MCA records. Its shares are listed on BSE: 530199 and NSE: THEMISMED.

The company has an authorised share capital of ₹10 Cr and a paid-up capital of ₹9.21 Cr. It is led by directors including Sachin Dinesh Patel (Managing Director) and Dinesh Shantilal Patel (Whole-Time Director).

Its last annual general meeting (AGM) was held on 12 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Plot No 69 – A GIDC Ind Estate Dist – Valsad, Vapi, Gujarat, India – 396195.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹342.24 Cr, a decline of 15.6% compared to the previous year. For the same year it recorded a net profit of ₹1.65 Cr (net margin 0.5%) and EBITDA of -₹48 Lakh (EBITDA margin -0.1%). The net worth stands at ₹398.58 Cr (down 1% YoY). Total assets are valued at ₹500.61 Cr (up 2.7% YoY).

The company has about 1,343 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries and 1 joint venture.

The company is associated with 1 brand: Themis Medicare. As per MCA filings, the company has open charges of ₹615.66 Cr and satisfied charges of ₹110.57 Cr on record. Court records list 212 cases involving the company, including 93 filed by the company and 119 filed against it; 37 cases are pending. The company has 10 deals on record (9 market trades, 1 acquisition); the latest was in October 2025. Its 8 peer companies in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Aspiro Pharma Limited with revenue of ₹418.29 Cr. The company has 15 MSME Form 1 returns on record between 2019 and 2024, listing 2,390 overdue payments to 149 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website themismedicare.com.

Company details

CIN L24110GJ1969PLC001590
Registration Number 001590
Incorporation Date 31 May 1969
ROC Ahmedabad
Listing Status Listed - Listed on NSE (THEMISMED); Listed on BSE (530199)
Company Status Active
Date of Last AGM 12 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Key People
Sachin Dinesh Patel Managing Director Dinesh Shantilal Patel Whole-Time Director Rajneesh Kedarnath Anand Director

Recognitions & Rankings of Themis Medicare

Contact details

Themis Medicare Limited's registered office is in Vapi, Gujarat. Its website is themismedicare.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    themismedicare.com
  • Social Media
  • Registered Address
    Plot No 69 – A GIDC Ind Estate Dist – Valsad, Vapi, Gujarat, India – 396195
  • Industry
    Pharma, API Manufacturers, Drug Formulation & Development

To see the full contact details of Themis Medicare Limited, buy the company report.

Comprehensive company report
Themis Medicare Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Themis Medicare operates one associated brand: Themis Medicare. Each brand links to its own profile.

BrandDescriptionWebsite
Themis Medicare
Pharmaceutical products for pain management and critical care are manufactured.themismedicare.com

Business activity

The main business activity of Themis Medicare is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Themis Medicare Limited, buy the company report.

Financials of Themis Medicare Limited

FY 2025-26 filings available

Themis Medicare Limited reported revenue of ₹342.24 Cr (down 15.6% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹342 Cr
-15.6% YoY
EBITDA
−₹0.48 Cr
-101.0% YoY
Profit After Tax
₹1.65 Cr
-94.5% YoY
Net Worth
₹399 Cr
-1.0% YoY
Total Assets
₹501 Cr
+2.7% YoY
Total Debt
₹100 Cr
+20.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue342406382354395231202
Revenue growth-15.6%+6.2%+7.7%-10.2%+71.1%+14.4%-
EBITDA(0.48)49.0451.5167.4395.6449.4835.66
EBITDA margin-0.1%+12.1%+13.5%+19.0%+24.2%+21.5%+17.7%
Profit before tax1.9239.6653.4472.5095.2741.3226.88
Net profit1.6529.8242.1654.3671.7235.1924.63
Net profit margin+0.5%+7.4%+11.0%+15.3%+18.2%+15.3%+12.2%
EPS (₹)0.123.244.7361.8379.2238.8626.97
Balance sheet
Total assets501487473432367306283
Net worth399403378339287219183
Total debt10082.9995.7992.3779.7387.1899.94
Cash & bank9.1512.8419.3018.8926.5024.635.29
Net working capital217212208189160121114
Cash flow
Cash from operations(3.27)34.7122.0916.0934.3956.980.33
Cash from investing(2.54)(12.17)(15.95)(23.96)(15.59)(15.65)(5.47)
Cash from financing3.79(25.90)(8.77)0.14(17.55)(25.65)6.72
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue86.9676.5390.1377.9997.5871.7093.81117
Revenue growth (YoY)-10.9%+6.7%-3.9%-33.4%-20.7%---
Other income96.5410.606.804.981.181.551.025.56
EBITDA(52.42)3.768.93(3.09)(10.22)(7.70)5.9717.13
EBITDA margin-60.3%+4.9%+9.9%-4.0%-10.5%-10.7%+6.4%+14.6%
Depreciation2.542.602.592.572.552.532.542.45
Interest2.982.702.752.762.472.452.792.44
Profit before tax38.609.0610.39(3.44)(14.06)(11.13)1.6617.80
Tax13.990.170.290.160.16(1.46)1.143.50
Net profit24.618.8910.10(3.60)(14.22)(9.67)0.5214.30
EPS (₹)2.670.961.09(0.39)(1.54)(1.05)0.061.55
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue342406382354395231202
Revenue growth-15.6%+6.2%+7.7%-10.2%+71.1%+14.4%-
EBITDA(1.77)49.0551.5367.4595.6549.8835.68
EBITDA margin-0.5%+12.1%+13.5%+19.0%+24.2%+21.6%+17.7%
Profit before tax(13.42)33.7534.6658.9083.9432.2418.00
Net profit(12.17)23.9124.7443.2961.5626.6115.91
Net profit margin-3.6%+5.9%+6.5%+12.2%+15.6%+11.5%+7.9%
EPS (₹)(1.54)2.602.6947.0466.9128.9717.32
Balance sheet
Total assets403405399374323273259
Net worth301320301282243186159
Total debt10082.9995.7992.3779.7387.1899.94
Cash & bank9.0612.7419.2018.8526.4924.625.28
Net working capital217213211191161122114
Cash flow
Cash from operations(3.27)34.7122.0416.0734.3956.980.33
Cash from investing(2.54)(12.17)(15.96)(23.96)(15.58)(15.65)(5.46)
Cash from financing3.79(25.90)(8.77)0.14(17.55)(25.65)6.72
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue86.9676.5390.1377.9997.5871.7093.81117
Revenue growth (YoY)-10.9%+6.7%-3.9%-33.4%-20.7%---
Other income1013.671.283.241.181.551.021.14
Total expenses13972.7681.2081.0810977.4885.2899.88
EBITDA(52.42)3.778.93(3.09)(11.37)(5.78)8.5317.13
EBITDA margin-60.3%+4.9%+9.9%-4.0%-11.7%-8.1%+9.1%+14.6%
Depreciation2.542.602.592.572.552.532.542.45
Interest2.982.702.752.762.472.452.792.44
Profit before tax42.722.144.87(5.18)(15.21)(9.21)4.2213.38
Tax13.990.170.290.160.16(1.46)1.143.50

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 31 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue86.9676.5390.1377.9997.5871.7093.81117
Revenue growth (YoY)-10.9%+6.7%-3.9%-33.4%-20.7%---
Other income96.5410.606.804.981.181.551.025.56
EBITDA(52.42)3.768.93(3.09)(10.22)(7.70)5.9717.13
EBITDA margin-60.3%+4.9%+9.9%-4.0%-10.5%-10.7%+6.4%+14.6%
Depreciation2.542.602.592.572.552.532.542.45
Interest2.982.702.752.762.472.452.792.44
Profit before tax38.609.0610.39(3.44)(14.06)(11.13)1.6617.80
Tax13.990.170.290.160.16(1.46)1.143.50
Net profit24.618.8910.10(3.60)(14.22)(9.67)0.5214.30
EPS (₹)2.670.961.09(0.39)(1.54)(1.05)0.061.55
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue342406382354395231202
Revenue growth-15.6%+6.2%+7.7%-10.2%+71.1%+14.4%-
Other income23.4110.5923.5625.1217.8813.1012.37
Total expenses343356330287299181166
Employee cost93.5296.3882.4166.1551.9739.9944.28
EBITDA(0.48)49.0451.5167.4395.6449.4835.66
EBITDA margin-0.1%+12.1%+13.5%+19.0%+24.2%+21.5%+17.7%
Depreciation10.329.9312.2510.499.488.558.27
Interest10.6910.049.389.568.7712.7112.88
Profit before tax1.9239.6653.4472.5095.2741.3226.88
Tax0.789.849.9215.6122.385.632.09
Net profit1.6529.8242.1654.3671.7235.1924.63
Net profit margin+0.5%+7.4%+11.0%+15.3%+18.2%+15.3%+12.2%
EPS (₹)0.123.244.7361.8379.2238.8626.97
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital9.219.209.209.209.209.199.19
Reserves & surplus389393368330278209174
Shareholders' funds (net worth)399403378339287219183
Minority interest0.000.000.000.000.000.000.00
Secured loans69.4556.9367.0461.6447.1549.0258.90
Unsecured loans30.6426.0628.7530.7332.5838.1641.04
Total debt10082.9995.7992.3779.7387.1899.94
Total liabilities501487473432367306283
Assets
Gross block254249239221192172147
Net block167172168162144133116
Capital work in progress2.472.512.602.602.562.477.54
Investments10994.7788.8970.0056.3144.9635.47
Inventories81.0984.3170.5768.9560.8158.4954.61
Sundry debtors17817717814510177.61102
Cash & bank balances9.1512.8419.3018.8926.5024.635.29
Loans & advances36.6229.6125.3631.6726.2924.7318.10
Total current assets305304293265214185180
Total current liabilities87.9391.7585.5675.2054.0864.5066.95
Net working capital217212208189160121114
Total assets501487473432367306283
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash6.569.9212.5520.2819.023.341.75
Net cash from operating activities(3.27)34.7122.0916.0934.3956.980.33
Net cash from investing activities(2.54)(12.17)(15.95)(23.96)(15.59)(15.65)(5.47)
Net cash from financing activities3.79(25.90)(8.77)0.14(17.55)(25.65)6.72
Net change in cash(2.02)(3.36)(2.62)(7.73)1.2615.681.59
Closing cash9.1512.8419.3018.8926.5024.635.29
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-15.6%+6.2%+7.7%-10.2%+71.1%+14.4%-
EBITDA growth-101.0%-4.8%-23.6%-29.5%+93.3%+38.8%-
PBT growth-95.2%-25.8%-26.3%-23.9%+130.6%+53.7%+9998.0%
Net income growth-94.5%-29.3%-22.4%-24.2%+103.8%+42.9%-
Revenue CAGR (3Y)-1.2%+0.9%+18.3%+20.7%+29.0%+3.3%-2.4%
EBITDA CAGR (3Y)--20.0%+1.4%+23.7%+248.0%+25.5%+2.8%
Profitability & leverage
Net income margin+0.3%+7.4%+11.4%+16.1%+18.5%+15.5%+12.3%
Return on capital employed+2.9%+11.1%+15.0%+22.5%+34.4%+20.8%+17.6%
Return on net worth+0.5%+8.4%+13.4%+20.4%+33.3%+21.5%+18.3%
Debt / equity0.250.250.290.310.380.560.67
Long-term debt / equity0.040.060.080.090.110.110.08
Interest cover-98.9825.6723.8916.7910.1831.0547.02
Efficiency & per share
Fixed asset turnover1.561.921.942.052.671.851.81
Inventory turnover4.145.245.475.466.624.083.72
Debtors turnover1.932.282.362.894.432.562.30
EPS (₹)0.123.244.7361.8379.2238.8626.97
Dividend per share (₹)0.500.500.505.005.004.301.75
Book value per share (₹)39.7440.1637.41332.15275.34200.18161.14
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue86.9676.5390.1377.9997.5871.7093.81117
Revenue growth (YoY)-10.9%+6.7%-3.9%-33.4%-20.7%---
Other income1013.671.283.241.181.551.021.14
Total expenses13972.7681.2081.0810977.4885.2899.88
EBITDA(52.42)3.778.93(3.09)(11.37)(5.78)8.5317.13
EBITDA margin-60.3%+4.9%+9.9%-4.0%-11.7%-8.1%+9.1%+14.6%
Depreciation2.542.602.592.572.552.532.542.45
Interest2.982.702.752.762.472.452.792.44
Profit before tax42.722.144.87(5.18)(15.21)(9.21)4.2213.38
Tax13.990.170.290.160.16(1.46)1.143.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue342406382354395231202
Revenue growth-15.6%+6.2%+7.7%-10.2%+71.1%+14.4%-
Other income9.364.674.7611.506.543.623.47
Total expenses344356330287299181166
Employee cost93.5296.3882.4166.1551.9739.9944.28
EBITDA(1.77)49.0551.5367.4595.6549.8835.68
EBITDA margin-0.5%+12.1%+13.5%+19.0%+24.2%+21.6%+17.7%
Depreciation10.329.9312.2510.499.488.558.27
Interest10.6910.049.389.568.7712.7112.88
Profit before tax(13.42)33.7534.6658.9083.9432.2418.00
Tax0.789.849.9215.6122.385.632.09
Net profit(12.17)23.9124.7443.2961.5626.6115.91
Net profit margin-3.6%+5.9%+6.5%+12.2%+15.6%+11.5%+7.9%
EPS (₹)(1.54)2.602.6947.0466.9128.9717.32
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital9.219.209.209.209.209.199.19
Reserves & surplus292311292273234177150
Shareholders' funds (net worth)301320301282243186159
Secured loans69.4556.9367.0461.6447.1549.0258.90
Unsecured loans30.6426.0628.7530.7332.5838.1641.04
Total debt10082.9995.7992.3779.7387.1899.94
Total liabilities403405399374323273259
Assets
Gross block254250236221192172147
Net block167172168162144133116
Capital work in progress2.472.512.602.602.562.477.54
Investments11.1211.1111.1711.0711.0110.9810.96
Inventories81.0984.3170.5768.9560.8158.4954.24
Sundry debtors17817717814510177.96103
Cash & bank balances9.0612.7419.2018.8526.4924.625.28
Loans & advances36.7330.6326.3732.6227.2125.6418.91
Total current assets305305294266215187181
Total current liabilities87.8791.6883.9075.1554.0564.4766.93
Net working capital217213211191161122114
Total assets403405399374323273259
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash6.479.8312.5120.2719.003.331.73
Net cash from operating activities(3.27)34.7122.0416.0734.3956.980.33
Net cash from investing activities(2.54)(12.17)(15.96)(23.96)(15.58)(15.65)(5.46)
Net cash from financing activities3.79(25.90)(8.77)0.14(17.55)(25.65)6.72
Net change in cash(2.02)(3.36)(2.68)(7.75)1.2615.681.60
Closing cash9.0612.7419.2018.8526.4924.625.28
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-15.6%+6.2%+7.7%-10.2%+71.1%+14.4%-
EBITDA growth-103.6%-4.8%-23.6%-29.5%+91.8%+39.8%-
PBT growth--2.6%-41.2%-29.8%+160.4%+79.1%+9998.0%
Net income growth-150.9%-3.4%-42.9%-29.7%+131.3%+67.3%-
Revenue CAGR (3Y)-1.2%+0.9%+18.3%+20.7%+28.9%+3.3%-2.4%
EBITDA CAGR (3Y)--20.0%+1.1%+23.7%+233.4%+24.8%+3.8%
Profitability & leverage
Net income margin-4.2%+5.9%+6.5%+12.2%+15.6%+11.5%+7.9%
Return on capital employed-0.2%+11.9%+12.5%+21.8%+35.2%+19.4%+14.9%
Return on net worth-4.4%+8.6%+9.6%+18.9%+34.2%+19.3%+13.7%
Debt / equity0.330.320.360.380.460.680.78
Long-term debt / equity0.050.080.110.120.130.130.09
Interest cover-88.4225.6623.8816.7810.1830.7546.99
Efficiency & per share
Fixed asset turnover1.561.931.962.052.671.851.81
Inventory turnover4.145.245.475.466.624.093.75
Debtors turnover1.922.282.362.884.412.552.29
EPS (₹)(1.54)2.602.6947.0466.9128.9717.32
Dividend per share (₹)0.500.500.505.005.004.301.75
Book value per share (₹)29.1431.2229.11269.54227.50164.59135.33

To see the full year-wise statements and ratios of Themis Medicare Limited, buy the company report.

Board of directors of Themis Medicare Limited

Themis Medicare has 9 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Rajneesh Kedarnath Anand
Also directs: Gujarat Themis Biosyn Ltd, Richter Themis Medicare (India) Private Limited, Long Island Nutritionals Private Limited
Director27 Apr 200719 Years 6 MonthsCurrent
Bhaskar Vemban Iyer
Also directs: Corona Remedies Limited, RPG Life Sciences Limited
Director12 Nov 20214 Years 11 MonthsCurrent
Dinesh Shantilal Patel
Also directs: Gujarat Themis Biosyn Ltd, Dr. Themis Private Limited, Richter Themis Medicare (India) Private Limited and 4 more
Whole-Time Director29 Jun 200719 Years 4 MonthsCurrent
Sachin Dinesh Patel
Also directs: Gujarat Themis Biosyn Ltd, Dr. Themis Private Limited, Richter Themis Medicare (India) Private Limited and 5 more
Managing Director29 Jun 200719 Years 4 MonthsCurrent
Reena Sachin Patel
Also directs: Vividhmargi Investments Private Limited, Protevista Business Advisors Limited, Kibitzer Property Ventures Limited and 3 more
Alternate Director11 Sep 20233 Years 1 MonthsCurrent
Neha Anant Thakore
Also directs: Relic Technologies Limited, Neema Consumer Global Private Limited, Anantco Pharmachem Private Limited and 1 more
Director01 Aug 20251 Years 3 MonthsCurrent
Showing 6 of 9 current directors. View all directors

Peer comparison

Themis Medicare Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Aspiro Pharma Limited₹418.29 Cr (FY 2025)147.0%Markook, Telangana, India
Scott-Edil Advance Research Laboratories & Education Limited₹418.23 Cr (FY 2025)17.0%Chandigarh, India
Senores Pharmaceuticals Limited₹417.51 Cr (FY 2025)92.0%Ahmedabad, Gujarat, India
Visa Drugs & Pharmaceuticals Private Limited₹414.04 Cr (FY 2016)32.0%Kolkata, West Bengal, India
Skymap Pharmaceuticals Private Limited₹409.08 Cr (FY 2025)2.0%New Delhi, Delhi, India
Penam Laboratories Limited₹407.63 Cr (FY 2025)-26.0%New Delhi, Delhi, India
Arene Life Sciences (Unit 4) Private Limited₹405.87 Cr (FY 2021)3.0%Hyderabad, Telangana, India
United Biotech Private Limited₹404.94 Cr (FY 2024)27.0%New Delhi, Delhi, India
Themis Medicare Limitedthis company₹342.24 Cr (FY 2026)₹1.65 Cr0.5%-15.6%1,343Vapi, Gujarat, India

To see the full peer comparison of Themis Medicare Limited, buy the company report.

Auditor

Themis Medicare Limited is audited by Krishaan & Co for the financial year 2024.

Auditor firmFinancial yearFirm registration number
Krishaan & CoFY 2024001453S

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 67.10%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 32.90%.

Promoters: 67.10%Retail & Others: 32.90%
Sep 2026
QUARTER
67.10% Promoters
32.90% Retail & Others
Promoter holding - history
Now 67.10% · Sep 2026High 67.20% · Dec 2025Low 67.10% · Mar 2026
66%66.8%67.5%68.3%69%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 67.20%Mar 2026: 67.10%Jun 2026: 67.10%Sep 2026: 67.10%67.20%67.10%67.10%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters67.10%67.10%67.10%67.20%
Public32.90%32.90%32.90%32.80%

Charges & borrowings

Open charges
₹615.66 Cr
Satisfied charges
₹110.57 Cr
Breakdown by lending institutions
Others₹343.43 Cr
Union Bank of India - Lead Bank of Ubi Consortium₹117.30 Cr
Union Bank of India₹111.91 Cr
Bank of Baroda₹36.79 Cr
The Zoroastrian Co-Operative Bank Limited₹6.00 Cr
Others₹0.23 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
15 Jun 2026101312589Others₹4.57 CrOpen
08 Jun 2026101310061Others₹15 CrOpen
31 Dec 2025101223555Others₹6 CrOpen
26 Dec 2025101242098Others₹13 CrOpen
21 Aug 2025101149019Others₹1 CrOpen

To see the full charge records of Themis Medicare Limited, buy the company report.

Total charge records: 50 View all charges

Deals & funding

Themis Medicare Limited has 10 deals on record (9 market trades, 1 acquisition); the latest was in October 2025.

Total deals
10
Market trades
9
Acquisition
1

Deals on record (5 of 10)

WhenDealAmountParties
Oct 2025Market trade₹19.06 CrBuyer: NK Securities Research Private Limited , Graviton Research Capital LLP
Seller: NK Securities Research Private Limited , Graviton Research Capital LLP
Jun 2021Market trade₹5.3 CrBuyer: Tejas Tradefin LLP
Mar 2013Market trade₹1.36 CrBuyer: an individual
Seller: Gagandeep Credit Capital Private Limited
Oct 2010Acquisition₹4.01 CrBuyer: Gedeon Richter Ltd.
Mar 2010Market trade₹8.52 CrBuyer: Themis Distributors Private Limited
Seller: an individual

To see the full deal history of Themis Medicare Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Themis Medicare Limited was last rated by Acuite on 08 Jun 2026.

Rating agencyRated onRating
Acuite08 Jun 2026

To see the full credit ratings and regulatory alerts of Themis Medicare Limited, buy the company report.

MSME payment delays

Themis Medicare Limited has 15 MSME Form 1 returns on record between 2019 and 2024, listing 2,390 overdue payments to 149 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 149)

SupplierAmount dueDue sinceReported on
Umeeka Packaging Private Limited
an individual supplier
Bhasin Packwell Pvt Ltd
an individual supplier
an individual supplier

To see the full MSME payment records of Themis Medicare Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Themis Medicare has 2 subsidiary companies, 1 joint venture, and 2 associated companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

2
Subsidiary companies
1
Joint ventures
2
Associated companies
Key subsidiaries
Company NameCINShares held
Artemis Biotech LimitedU24233MH2011PLC212359
Themis Chemicals Private LimitedU33111MH2010PTC209797

To see the full group structure of Themis Medicare Limited, buy the company report.

Employees & EPFO

Themis Medicare Limited has a workforce of 1,343 employees on its EPFO records as of Apr 07, 2024, across 3 active EPFO establishments.

Employee count
1,343
Active EPFO establishments
3
Employee growth
14.49%

GST

No GST registration is on our record for Themis Medicare Limited; the GSTIN and return-filing check is in the company report Buy the company report.

Recent activity

Themis Medicare Limited has 43 board changes on record since 1969: 27 appointments and 16 cessations. The latest: Manjul Sandhu ceased to be Director on 10 Nov 2025.

Charges
A charge with Others amounted to Rs. 4.57 Cr with Charge ID 101312589 was registered on 15 Jun 2026.
Charges
A charge with Others amounted to Rs. 15.00 Cr with Charge ID 101310061 was registered on 08 Jun 2026.
Filing
Themis Medicare Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge with Others amounted to Rs. 6.00 Cr with Charge ID 101223555 was registered on 31 Dec 2025.
Charges
A charge with Others amounted to Rs. 13.00 Cr with Charge ID 101242098 was registered on 26 Dec 2025.
Ceased
Manjul Sandhu ceased to be Director.
Charges
A charge registered on 27 Oct 2020 via Charge ID 100389113 with Hdfc Bank Limited was fully satisfied on 06 Nov 2025.
Charges
A charge registered on 06 Feb 2024 via Charge ID 100858301 with Others was fully satisfied on 31 Oct 2025.
AGM
Themis Medicare Limited last Annual general meeting of members was held on 12 Sep 2025 as per latest MCA records.
Charges
A charge with Others amounted to Rs. 1.00 Cr with Charge ID 101149019 was registered on 21 Aug 2025.
Appointed
Neha Anant Thakore was appointed as Director.
Charges
A charge with The Zoroastrian Co-Operative Bank Limited of Rs. 6.00 Cr registered on 23 Jul 2015 with Charge ID 10587579 was modified on 08 Jul 2025.

99 earlier events are in the company report.

News

Frequently asked questions

Themis Medicare is an active public limited company based in Vapi, Gujarat, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 31 May 1969 (57+ years old) and is registered under CIN L24110GJ1969PLC001590. Listed on BSE: 530199 and NSE: THEMISMED.

Themis Medicare reported revenue of ₹342.24 Cr for FY 2025-26 (down 15.6% YoY) based on consolidated financials.

Themis Medicare has 9 current directors:

The latest financial statements of Themis Medicare on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 12 September 2025. Year-wise statements from 2015 are in the company report.

The CIN (Corporate Identification Number) of Themis Medicare is L24110GJ1969PLC001590. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Themis Medicare is a listed company as per MCA records. Its shares are listed on both BSE (code: 530199) and NSE (symbol: THEMISMED).

Themis Medicare has 212 court cases on record: 93 filed by the company and 119 filed against it. 37 are pending. Most are in the district courts.

Themis Medicare was incorporated on 31 May 1969, making it 57+ years old. It is registered with the Registrar of Companies, Ahmedabad.

Themis Medicare has 10 deals on record (9 market trades, 1 acquisition); the latest was in October 2025.

The peers of Themis Medicare by revenue are Aspiro Pharma Limited, Scott-Edil Advance Research Laboratories & Education Limited, Senores Pharmaceuticals Limited, Visa Drugs & Pharmaceuticals Private Limited, Skymap Pharmaceuticals Private Limited and 3 more, all in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Manjul Sandhu ceased to be Director on 10 Nov 2025. Neha Anant Thakore was appointed as Director on 01 Aug 2025. Pradeep Manjunath Chandan was appointed as Company Secretary on 14 Aug 2024. Themis Medicare has 43 board changes on record in total.

Themis Medicare has 15 MSME Form 1 returns on record between 2019 and 2024, listing 2,390 overdue payments to 149 micro and small suppliers. The latest return was filed on 27 May 2024.